<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03377426</url>
  </required_header>
  <id_info>
    <org_study_id>CLYS228X2201</org_study_id>
    <nct_id>NCT03377426</nct_id>
  </id_info>
  <brief_title>LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)</brief_title>
  <official_title>A Randomized, Controlled, Evaluator-blinded, Multi-center, Study to Evaluate LYS228 Pharmacokinetics, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate whether LYS228 can be developed for the treatment of
      complicated urinary tract infections
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 8, 2018</start_date>
  <completion_date type="Anticipated">June 17, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 17, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>A blinded evaluator will perform the safety and efficacy assessments</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline of the Clinical Response at Day 7</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>Clinical success at 7 days after randomization determined by signs and symptoms of infection and the need for additional antibiotics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of LYS228: Area Under the Plasma Concentration-time Curve from time zero to the end of dosing interval tau (AUCtau)</measure>
    <time_frame>Day 5</time_frame>
    <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of LYS228: The observed maximum plasma concentration following drug administration (Cmax)</measure>
    <time_frame>Day 5</time_frame>
    <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of LYS228: The time to reach the maximum concentration after drug administration (Tmax)</measure>
    <time_frame>Day 5</time_frame>
    <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of LYS228: The systemic (or total body) clearance from plasma following intravenous administration (CL)</measure>
    <time_frame>Day 5</time_frame>
    <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of LYS228: The volume of distribution at steady state following intravenous administration (Vss)</measure>
    <time_frame>Day 5</time_frame>
    <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of LYS228: The terminal elimination half-life (T 1/2)</measure>
    <time_frame>Day 5</time_frame>
    <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of LYS228: The amount of time in which the unbound drug concentration exceeds the minimum inhibitory concentration of the organism (%fT&gt;MIC)</measure>
    <time_frame>Day 5</time_frame>
    <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Pharmacokinetics (PK) of LYS228: The amount of drug eliminated in Urine from 0 hours up to 6 hours following intravenus administration (Ae0-6h)</measure>
    <time_frame>Day 5</time_frame>
    <description>Calculated based on LYS228 concentration in urine at different time points following drug administration on Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Pharmacokinetics (PK) of LYS228: Renal Clearance (CLr)</measure>
    <time_frame>Day 5</time_frame>
    <description>Calculated based on LYS228 concentration in urine at different time points following drug administration on Day 5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of the Microbiological Response at Day 7</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>Microbiologic success at 7 days after randomization determined by microbial growth in urine culture</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Complicated Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>LYS228</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV infusion of standard of care antibiotics for at least 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LYS228</intervention_name>
    <description>LYS228 IV infusion</description>
    <arm_group_label>LYS228</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care therapy</intervention_name>
    <description>IV infusion of standard of care antibiotics</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients 18 to 85 years of age with suspected and/or bacteriologically
             documented complicated UTI judges by the investigator to be serious (required patient
             to be hospitalized for treatment with intravenous antibiotics)

        Exclusion Criteria:

          -  Urine Gram stain that demonstrated that a Gram-positive organism was present, or if
             urine culture results were available, demonstrated Gram- positive organisms were
             present at â‰¥105 CFU/mL

          -  Urine culture result available at enrollment and demonstrating more than 2 different
             species of microorganisms regardless of the colony count

          -  Urine culture result available demonstrating fungal UTI with colony count &gt;103 CFU/mL

          -  Patient had received prior antibiotics within 72 hours before the initiation of study
             therapy

          -  Patients with estimated glomerular filtration rate &lt; 30mL/min calculated based in
             study qualified formula
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2017</study_first_submitted>
  <study_first_submitted_qc>December 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary tract infection, LYS228, beta-lactam antibiotics, creatinine clearance, Enterobactericeae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

